

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/738,413
Filing Date	December 17, 2003
First Named Inventor	Binetti, R.
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	SC66U-US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		BEHLKE, Mark A., Progress Towards in Vivo Use of siRNAs, Molecular Therapy, April 2006, p. 640-670, Vol. 13.	
		FILLEUR, S. et al., SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor..., Cancer Research 63, July 15, 2003, p. 3919-3922.	
		LEWIS, D. et al., Efficient delivery of siRNA for inhibition of gene expression in postnatal mice, Nature Genetics, September 2002, p. 107-108, Vol. 32.	
		MAEDA, Y. et al., In vitro and in vivo suppression of GJB2 expression by RNA interference, Human Molecular Genetics, 2002, p. 1641-1650, Vol. 14, No. 12.	
		MEHTA R., et al., Intercellular Adhesion Molecule-1 Suppression in Skin..., Soc. for Investigative Dermatology, Inc., Nov. 2000, p. 805-812, Vol. 115, No. 5.	
		PALLISER, D., et al., An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection, Nature, Jan. 2006, p. 89-94, Vol. 439, Issue 7072.	
		REICH, S. et al., Small interfering RNA(siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model, Molecular Vision, 2003, p. 210-216.	
↓		WRAIGHT, C., et al., Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor..., Nature Biotechnology, May 2000, p. 521-526, Vol. 18.	

Examiner
Signature

/Amy Bowman/

Date
Considered

11/27/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.